Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
National Cancer Institute (NCI)
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Mayo Clinic
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Duke University
Mayo Clinic
Mayo Clinic
University of Kansas Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
NRG Oncology
Emory University
National Cancer Institute (NCI)
Thomas Jefferson University
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Mayo Clinic
National Cancer Institute (NCI)